drugset / Trial / NCT05719012

Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19

NCT05719012

Phase 2 Withdrawn Shanghai East Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

To explore the efficacy and safety of Umbilical cord mesenchymal stem cells in the treatment of long COVID-19

Timeline

Start
2023-04-01
Primary completion
2023-12-01
Completion
2024-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy Intravenous

Indications